Orange Book product · Generic (ANDA)
CYTARABINE
CYTARABINE
At a glance
Aug 02, 1989
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Aug 02, 1989
37 yr 5 mo ago
Today
Pharmaceutical detail
Active ingredient
CYTARABINE
Strength
100MG/VIAL
Dosage form
INJECTABLE
Route
INJECTION
TE code
AP
Application
ANDA 071471
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of CYTARABINE
- 1999DEPOCYTBrand (NDA)
NDA 021041 · PACIRA PHARMS INC
- 1987CYTARABINEBrand (NDA)
NDA 016793 · TEVA PARENTERAL
- 2022CYTARABINEGeneric (ANDA)
ANDA 208485 · MEITHEAL
- 2020CYTARABINEGeneric (ANDA)
ANDA 206189 · MEITHEAL
- 2019CYTARABINEGeneric (ANDA)
ANDA 211938 · GLAND
- 2019CYTARABINEGeneric (ANDA)
ANDA 211937 · GLAND
- 2018CYTARABINEGeneric (ANDA)
ANDA 205696 · MEITHEAL
- 2017CYTARABINEGeneric (ANDA)
ANDA 206190 · MEITHEAL
- 2012CYTARABINEGeneric (ANDA)
ANDA 201784 · RISING
- 2011CYTARABINEGeneric (ANDA)
ANDA 200916 · PHARMOBEDIENT
- 2011CYTARABINEGeneric (ANDA)
ANDA 200914 · RISING
- 2011CYTARABINEGeneric (ANDA)
ANDA 200915 · RISING
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
